Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer

Trial Details

NCT ID

NCT06478225

Phase

NA

Sponsor

RenJi Hospital

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• BGT007H Cell Injection

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• voluntarily sign an informed consent form in writing.
• Age ≥18 years and ≤75 years, both male and female are eligible.
• Expected survival ≥ 3 months.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.